Protocol name: Phase II Neoadjuvant trial of Nivolumab in Combination with HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIc, IVM1a Melanoma (Neo-NivoHF10) Version Date: 22JUL2019 Principal Investigator: John Hyngtrom, MD Phase II Neoadjuvant trial of Nivolumab in Combination with HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma (Neo-NivoHF10) Trial ID: HCI102346/ IRB#102346 Drug Manufacturer protocol # CA209-9F3 NCT03259425 Principal Investigator John Hyngstrom, MD Huntsman Cancer Institute/University of Utah 2000 Circle of Hope Drive Salt Lake City, UT 84112 801-585-0255
[email protected] Sub-investigator(s) Brittany Thomas, PA-C Huntsman Cancer Institute/University of Utah
[email protected] Elizabeth Flores, PA Huntsman Cancer Institute/University of Utah
[email protected] Carolyn Luckett, APRN Huntsman Cancer Institute/University of Utah
[email protected] Siwen Hu-Lieskovan, MD Huntsman Cancer Institute/University of Utah
[email protected] Protocol name: Phase II Neoadjuvant trial of Nivolumab in Combination with HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIc, IVM1a Melanoma (Neo-NivoHF10) Version Date: 22JUL2019 Principal Investigator: John Hyngtrom, MD Kenneth Grossmann, MD Huntsman Cancer Institute/University of Utah
[email protected] Statistician Kenneth Boucher, PhD Huntsman Cancer Institute/University of Utah
[email protected] Drug Manufacturer Takara Bio Inc. Nojihigashi 7-4-38, Kusatsu Shiga 525-0058,